聚乙二醇干扰素治疗非活动性HBsAg携带者血清MIP-1β水平变化趋势  

Changes of serum levels of MIP-1β in inactive hepatitis B surface antigen carriers treated with pegylated-interferon

作　　者：曹振环[1] 柳雅立[1] 马丽娜[1] 郑燕红[1] 王群[1] 王俊丽[1] 吴芳芳[1] 陈新月[1] CAO Zhen-huan;LIU Ya-li;MA Li-na;ZHENG Yan-hong;WANG Qun;WANG Jun-li;WU Fang-fang;CHEN Xin-yue(Department of Liver Diseases,Beijing You＇an Hospital,Capital Medical University,100069,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病综合科,100069

出　　处：《传染病信息》2018年第5期436-438,457,共4页Infectious Disease Information

基　　金：国家"十三五"科技重大专项(2017ZX10202201);首都临床特色应用研究与成果推广(Z161100000516018;Z171100001017062);首都卫生发展科研专项(首发2016-1-2183;首发2018-2-2183);北京市自然科学基金(7182073);北京市医院管理局"青苗"计划(QML20161701);北京市教育委员会科技计划一般项目(KM201710025018);首都医科大学基础与临床合作项目(17JL-07);首都医科大学重点实验室开放研究课题(2-03-02-BJYAH2016001)

摘　　要：目的探讨聚乙二醇干扰素(pegylated-interferon, Peg-IFN)治疗非活动性HBsAg携带者(inactive hepatitis B surface antigen carrier, IHC)发生HBsAg清除与血清MIP-1β水平的相关性。方法入组经Peg-IFN治疗24周的IHC 20例,其中13例获得HBsAg清除(R组),7例未获得HBsAg清除(NR组)。用Luminex技术检测IHC基线、治疗12周和治疗24周血清巨噬细胞炎性蛋白1β(macrophage inflammatory protein-1β, MIP-1β)水平。同时检测11例健康者(HC组)血清MIP-1β水平。通过比较R组与NR组基线血清MIP-1β水平及治疗后变化趋势,探讨血清MIP-1β与HBsAg清除的相关性。结果 R组、NR组、HC组基线血清MIP-1β水平差异无统计学意义(F=0.320,P=0.729)。R组经Peg-IFN治疗后MIP-1β水平较基线明显下降(F=4.532,P=0.018)。而NR组血清MIP-1β呈水平波动,较基线无显著变化(F=0.071,P=0.932)。结论经Peg-IFN治疗后,IHC的血清MIP-1β水平明显降低,表明该治疗可能有利于HBsAg的清除。Objective To investigate the correlation of HBsAg clearance with serum MIP-1β level in inactive hepatitis B surface antigen carrier （IHC） treated with pegylated-interferon （Peg-IFN）. MethodsTwenty IHCs were enrolled in this study after 24 weeks of Peg-IFN treatment, including 13 patients achieving HBsAg clearance （R group） and 7 patients not achieving HBsAg clearance （NR group）. Serum MIP-1β levels in IHCs were detected by Luminex technology at baseline after 12 weeks and 24 weeks of treatment. In addition, serum MIP-1β levels in 11 healthy controls （HC group） were detected. The correlation of serum MIP-1β with HBsAg clearance was investigated by comparing the baseline serum MIP-1β level and post-treatment trends of R and NR groups. ResultsThere were no statistical significant differences of serum MIP-1β level between R, NR and HC groups （F=0.320, P=0.729）. After Peg-IFN treatment, serum MIP-1β level decreased significantly in R group, comparing to baseline data （F=4.532, P=0.018）. Serum MIP-1β level showed a horizontal fluctuation and no significantly change in NR group, comparing to baseline data （F=0.071, P=0.932）. ConclusionsAfter Peg-IFN treatment, serum MIP-1β level in IHC obviously decreases. This treatment may benefit HBsAg clearance.

关 键 词：非活动性HBSAG携带者 聚乙二醇干扰素 HBsAg清除 MIP-1Β 

分 类 号：R512.62[医药卫生—内科学]